Treatment of short normal children with longterm GH therapy or treatment with GnRH analogues to prolong prepubertal growth and thereby improve adult height produced disappointing results. This study was undertaken to assess whether the final height of pubertal, short normally growing children will improve on combined therapy: (for 18-24 months) GnRH analogue (Decapeptyl) 3.75 mg every 4 weeks to arrest puberty and rhGH (Saizen) 1 unit/kg BW/week to accelerate growth. This study comprised 13 boys mean age: 13.2±1 y Tanner stage II-III, bone age: 11.9±1 y height: 139.7±4.6cm and-2.42±1.2 SDS mid parental height 161±1.3cm (mean±SD). Six girls aged 10.8±0.8 Tanner stage II-III bone age 10.9±0.5y, 132.5±4.3cm and -1.57±1.4 SDS, mid parental height 164±4.4 (mean±SD). No adverse effects were observed. In spite of suppression of the reproductive axis all the children continued to grow. Ten boys achieved final height of 162.5±4. The mean increase in height percent was 17.6 (15.4-21.9%) 7 boys reached height higher than their mid-parental height and 6 improved their SDS, although the SDS and the target height for the whole group was higher, it was not significantly different. Four girls reached their final height of 152.8±0.8cm much lower than the mid-parental height. The mean increase in height percent was only 13.3±2.5. Only 2 girls improved their SDS, thus, although the girls were younger and had younger bone age their results were less promising. Further analysis of the data will help to predict who will gain from this treatment modality.